Related references
Note: Only part of the references are listed.
Letter
Medicine, General & Internal
Alicia T. Widge et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jennifer M. Dan et al.
Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.
Article
Multidisciplinary Sciences
Eric H. Y. Lau et al.
Summary: In this study, researchers quantified SARS-CoV-2 specific neutralizing antibodies using plaque reduction neutralization (PRNT) assays on 195 patients in different disease states. They found that patients with severe disease had higher peaks of neutralizing antibody titres than patients with mild or asymptomatic infections, and that serum neutralizing antibody persists for over 6 months in most people.
NATURE COMMUNICATIONS
(2021)
Review
Physiology
Varnica Bajaj et al.
Summary: The novel coronavirus has greatly impacted the world with over 72 million cases and 1.6 million deaths, mostly affecting the elderly population. Aging leads to changes in the immune system, making elderly individuals more susceptible to infections and less responsive to vaccines. Understanding age-related immune system changes is crucial for managing infectious diseases like COVID-19.
FRONTIERS IN PHYSIOLOGY
(2021)
Article
Medicine, General & Internal
Marion Cremoni et al.
Summary: Frontline health care workers exposed to SARS-CoV-2 show a robust immune response with high production of type I and II interferons, which may be protective against COVID-19. Additionally, HCWs with mild or asymptomatic forms of COVID-19 exhibit lower specific IgA and IgG levels, reflective of their mild symptoms.
FRONTIERS IN MEDICINE
(2021)
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Article
Biochemistry & Molecular Biology
Xuping Xie et al.
Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.
Letter
Medicine, General & Internal
Florian Krammer et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Yang Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cell Biology
Chloe Rees-Spear et al.
Summary: The study found that emerging variants of the coronavirus may lead to reduced neutralization by antibodies induced by vaccines or previous infection, but some samples still retain effectiveness. This highlights the importance of real-time monitoring of emerging mutations and their impact on vaccine efficacy.
Article
Biochemistry & Molecular Biology
Matthew McCallum et al.
Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.
Article
Infectious Diseases
Irene Cassaniti et al.
Summary: The study evaluated the SARS-CoV-2 T-cell response in COVID-19 convalescent patients and unexposed individuals, showing that a majority of convalescent patients had a positive response to at least one SARS-CoV-2 antigen, which could last up to 12 months. The findings suggest that the SARS-CoV-2 T-cell response is primarily mediated by CD4 T cells.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Letter
Medicine, General & Internal
Venkata Viswanadh Edara et al.
Summary: This study investigates the neutralizing antibody response to 4 SARS-CoV-2 variants in individuals who have been infected or vaccinated.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Immunology
Frauke Muecksch et al.
Summary: This study examined the development of antibodies following infection with the coronavirus, finding that evolved antibodies had increased affinity and neutralization potency, altered mutational pathways for viral resistance, and restricted neutralization escape options. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying populations of the virus and other pandemic threat coronaviruses.
Article
Microbiology
Jia Wei et al.
Summary: A longitudinal study on 45,965 adults in the UK revealed that older individuals, especially those aged >60 years, had lower antibody levels after a single dose of ChAdOx1 or BNT162b2 COVID-19 vaccines. Prioritizing vaccine allocation for those not previously infected and older individuals for the second dose is recommended based on the findings. Further data is needed to fully understand the relationship between quantitative antibody responses and vaccine-mediated protection.
NATURE MICROBIOLOGY
(2021)
Article
Immunology
Alberto Zani et al.
Summary: The study demonstrates that antibodies generated by the BNT162b2 vaccine can efficiently neutralize authentic viruses belonging to various SARS-CoV-2 lineages. Neutralization was highest for B.1.1.7 and B.1.525 lineages, while lower for B.1.351 and P.1 lineages compared to the B.1 lineage. The findings suggest that the BNT162b2 vaccine offers protection against the prevailing variants of SARS-CoV-2.
EMERGING MICROBES & INFECTIONS
(2021)
Letter
Infectious Diseases
Sonia Jangra et al.
Article
Virology
Niko Kohmer et al.
JOURNAL OF CLINICAL VIROLOGY
(2020)
Article
Biotechnology & Applied Microbiology
Chee Wah Tan et al.
NATURE BIOTECHNOLOGY
(2020)
Article
Biology
Yiska Weisblum et al.
